A dietetics professor explains who should and should not embrace the latest weight-loss drugs. Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

The new administration is likely to take significant actions that will impact employer-sponsored health insurance and federal ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion ...

Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

Eli Lilly and Company’s LLY shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 ...

Weight loss jabs such as Wegovy are “lifelong treatments” and most people who stop taking them will lose the effects, a ...

When drugmakers pulled the weight-loss drug fen-phen off the market in 1997, my mom was devastated. Not because the FDA ...

It's not just celebrities and TikTok creators jumping on the weight loss drug hype - more than 500,000 people in the UK are ...

Users of the popular weight loss drugs are shunning items like energy drinks and salty snacks, research shows. But there are ...

A more “accurate” and “nuanced” definition of obesity is necessary worldwide if global health authorities and governments are ...